Loading...
XNAS
OCX
Market cap150mUSD
, Last price  
USD
Name

OncoCyte Corp

Chart & Performance

D1W1MN
XNAS:OCX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
38.50%
Rev. gr., 5y
0.00%
Revenues
2m
+25.15%
00000001,216,0007,727,000958,0001,503,0001,881,000
Net income
-61m
L+118.36%
-3,495,000-4,986,000-8,735,000-11,168,000-19,375,000-15,754,000-22,329,000-29,932,000-64,097,000-73,440,000-27,781,000-60,663,000
CFO
-21m
L-11.20%
-710,000-1,164,000-4,229,000-7,522,000-13,385,000-11,649,000-19,715,000-25,980,000-35,941,000-45,568,000-23,325,000-20,713,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
URL
https://oncocyte.com/
IPO date
Dec 30, 2015
Employees
75
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT